<DOC>
	<DOC>NCT00146159</DOC>
	<brief_summary>The purpose of this study is to show the dose-response relationship of three doses of mitoxantrone with regard to efficacy in patients with secondary progressive multiple sclerosis and to show the safety and tolerability of mitoxantrone in these patients.</brief_summary>
	<brief_title>Study Evaluating Mitoxantrone in Multiple Sclerosis</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
	<mesh_term>Mitoxantrone</mesh_term>
	<criteria>Secondary progressive MS in an active stage EDSS between 3 and 6 Benign or primary progressive MS Patients with cardiac risk factors Patients who have already received mitoxantrone</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2007</verification_date>
	<keyword>Multiple Sclerosis</keyword>
</DOC>